{"title": "Prev\u00e9n pruebas cl\u00ednicas de vacunas de COVID-19 a mediados de abril o antes", "author": null, "url": null, "hostname": null, "description": "Trabajadores laboran en el laboratorio integral de salud y cuarentena del Centro de Salud de Vi", "sitename": null, "date": "2020-03-07", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Trabajadores laboran en el laboratorio integral de salud y cuarentena del Centro de Salud de Viajes Internacionales de Sichuan, en Chengdu, en la provincia de Sichuan, en el suroeste de China, el 15 de febrero de 2020. (Xinhua/Liu Kun)\nWUHAN, 6 mar (Xinhua) -- Algunas vacunas contra el COVID-19 podr\u00edan entrar en etapa de prueba cl\u00ednica para mediados de abril o incluso antes, se\u00f1al\u00f3 hoy viernes un funcionario.\nLos cient\u00edficos chinos est\u00e1n apresur\u00e1ndose para hacer avances cient\u00edficos y tecnol\u00f3gicos en la prevenci\u00f3n y control epid\u00e9micos adoptando cinco enfoques tecnol\u00f3gicos, dijo el subsecretario general del Consejo de Estado, Ding Xiangyang, durante una conferencia de prensa en Wuhan, el epicentro del brote del nuevo coronavirus.\nEl pa\u00eds ha adoptado m\u00e9todos de tratamiento que combinan la medicina tradicional china (MTCh) con la occidental para curar a los pacientes de COVID-19 y realizaron pruebas y estudios cl\u00ednicos en distintos tipos de pacientes, incluyendo a los de s\u00edntomas leves, luego de examinar m\u00e1s de 5.000 tipos de medicamentos. El tratamiento de MTCh ha rendido buenos resultados, evitando que los pacientes con s\u00edntomas leves se agravaran, dijo Ding.\nHasta el 3 de marzo, un total de 14 tipos de reactivos de prueba de \u00e1cido nucleico hab\u00edan sido puestos a disposici\u00f3n mediante una aprobaci\u00f3n de emergencia.(Web editor: \u8d75\u5065, Rosa Liu)", "language": null, "image": null, "pagetype": null, "links": ["http://spanish.peopledaily.com.cn/", "http://spanish.peopledaily.com.cn/", "http://spanish.peopledaily.com.cn/31621/index.html", "http://spanish.peopledaily.com.cn/31620/index.html", "http://spanish.peopledaily.com.cn/31618/index.html", "http://spanish.peopledaily.com.cn/31617/index.html", "http://spanish.peopledaily.com.cn/31619/index.html", "http://spanish.peopledaily.com.cn//92121/index.html", "http://spanish.peopledaily.com.cn/31615/index.html", "http://spanish.peopledaily.com.cn//92122/index.html", "http://spanish.peopledaily.com.cn/31614/index.html", "http://spanish.peopledaily.com.cn/204699/index.html", "http://spanish.peopledaily.com.cn/31613/index.html", "http://spanish.peopledaily.com.cn//101336/index.html", "http://spanish.peopledaily.com.cn/205763/index.html", "http://spanish.peopledaily.com.cn/", "http://spanish.peopledaily.com.cn/92121/", "http://spanish.xinhuanet.com/", "/32001/415994/index.html", "http://103.42.76.205/spain/index.php/comment/netuser/9665730", "/n3/2017/0620/c31614-9230854.html", "/n3/2017/0620/c92122-9230905.html", "/n3/2017/0621/c92121-9231296.html", "/n3/2017/0621/c31614-9231439.html", "/n3/2017/0621/c31620-9231352.html", "/n3/2017/0621/c31620-9231441.html", "/n3/2017/0621/c31619-9231418.html", "/n3/2020/0307/c31621-9665721.html", "/n3/2020/0307/c31621-9665721.html", "/n3/2020/0307/c31621-9665717.html", "/n3/2020/0307/c31621-9665717.html", "/n3/2020/0306/c31614-9665548.html", "/n3/2020/0305/c92121-9665144.html", "/n3/2020/0305/c92121-9665144.html", "/n3/2020/0305/c92122-9665141.html", "/n3/2020/0305/c92122-9665120.html", "/n3/2020/0305/c92122-9665120.html", "/n3/2020/0305/c31614-9665099.html", "/n3/2020/0305/c31614-9665099.html", "/n3/2020/0305/c92122-9664843.html", "/n3/2020/0305/c92122-9664843.html", "/n3/2020/0304/c31621-9664833.html", "/n3/2020/0304/c31614-9664747.html"]}